Impact of CYP2C9 genotype on pharmacokinetics:: Are all NSAIDs the same? -: Reply

被引：0
|
作者：
Pilotto, Alberto [1 ]
Franceschi, Marilisa
Scarcelli, Carlo
Niro, Valeria
Seripa, Davide
Colaizzo, Donatella
Grandone, Elvira
Andrjulli, Angelo
Dallapiccola, Bruno
Di Mario, Francesco
Leandro, Gioacchino
机构：
[1] IRCCS Casa Sollievo Sofferenza, Dept Med Sci, Geriatr Unit, San Giovanni Rotondo, Italy
[2] IRCCS Casa Sollievo Sofferenza, Dept Res, Lab Gerontol & Geriatr, San Giovanni Rotondo, Italy
[3] Univ Parma, Dept Gastroenterol, I-43100 Parma, Italy
[4] IRCCS Casa Sollievo Sofferenza, Dept Res, Lab Atherosclerosis & Thrombosis, San Giovanni Rotondo, Italy
[5] IRCCS Casa Sollievo Sofferenza, Dept Med Sci, Gastroenterol Unit, San Giovanni Rotondo, Italy
[6] CSS Mendel Inst, Rome, Italy
[7] IRCCS Saverio De Bellis, Gastroenterol Unit, Castellana Grotte, Italy
来源：
GASTROENTEROLOGY | 2007年 / 133卷 / 06期
关键词：
D O I：
10.1053/j.gastro.2007.10.020
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：2074 / 2075
页数：2
相关论文
共 50 条
  • [41] Effects of CYP2C9*3 and CYP2C9*13 alleles on the pharmacokinetics of celecoxib and its carboxylic metabolite.
    Park, So-Young
    Lee, Hye-In
    Choi, Chang-Ik
    PHARMACOTHERAPY, 2012, 32 (10): : E235 - E235
  • [42] Allele and genotype frequencies of CYP2C9 in a Korean population
    Bae, JW
    Kim, HK
    Kim, JH
    Yang, SI
    Kim, MJ
    Jang, CG
    Park, YS
    Lee, SY
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 60 (04) : 418 - 422
  • [43] INDUCTION OF CYP2C9 IN A POOR METABOLIZER GENOTYPE.
    Sun, G.
    Gryn, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 : S52 - S52
  • [44] Differential genotype dependent inhibition of CYP2C9 in humans
    Kumar, Vikas
    Brundage, Richard C.
    Oetting, William S.
    Leppik, Ilo E.
    Tracy, Timothy S.
    DRUG METABOLISM AND DISPOSITION, 2008, 36 (07) : 1242 - 1248
  • [45] Metabolism of lornoxicam in relation to CYP2C9 genotype status
    Kim, Dong-Hyun
    Lim, Hye-Jin
    Byeon, Ji-Yeong
    Kim, Young-Hoon
    Kim, Se-Hyung
    PHARMACOTHERAPY, 2015, 35 (11): : E316 - E316
  • [46] Allele and genotype frequency of CYP2C9 in Tamilnadu population
    Adithan, C
    Gerard, N
    Vasu, S
    Balakrishnan, R
    Shashindran, CH
    Krishnamoorthy, R
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 59 (8-9) : 707 - 709
  • [47] Consequences of CYP2C9 polymorphisms on flurbiprofen pharmacokinetics.
    Lee, CR
    Pieper, JA
    Frye, RF
    Hinderliter, AL
    Blaisdell, JA
    Goldstein, JA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (02) : P62 - P62
  • [48] Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of zafirlukast
    Hyun-Jee Lee
    Young-Hoon Kim
    Se-Hyung Kim
    Choong-Min Lee
    Ae-Yun Yang
    Choon-Gon Jang
    Seok-Yong Lee
    Jung-Woo Bae
    Chang-Ik Choi
    Archives of Pharmacal Research, 2016, 39 : 1013 - 1019
  • [49] EFFECTS OF CYP2C9☆13 ALLELE ON THE PHARMACOKINETICS OF IRBESARTAN
    Park, J., I
    Choi, C., I
    Bae, J. W.
    Jang, C. G.
    Lee, S. Y.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2011, 109 : 64 - 64
  • [50] The effect of bucolome, a CYP2C9 inhibitor, on the pharmacokinetics of losartan
    Kobayashi, Mariko
    Takagi, Miho
    Fukumoto, Kyoko
    Kato, Ryuji
    Tanaka, Kazuhiko
    Ueno, Kazuyuki
    DRUG METABOLISM AND PHARMACOKINETICS, 2008, 23 (02) : 115 - 119
12345